A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

Leukemia and Lymphoma

Volumn 52, Issue 3, 2011, Pages 394-399

  Kouroukis, C Tom ^a   Fernandez, Louis A V ^b   Crump, Michael ^c   Chua, Neil Sun ^d   Buckstein, Rena ^e   Turner, Robert ^d   Assouline, Sarit ^f   Klasa, Richard J ^g   Walsh, Wendy ^h   Powers, Jean ^h   Eisenhauer, Elizabeth ^h  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h National Cancer Institute of Canada Clinical Trials Group   (Canada)

Author keywords

bortezomib; gemcitabine; Mantle cell lymphoma; phase II

Indexed keywords

BORTEZOMIB; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOODSTREAM INFECTION; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; COUGHING; DEHYDRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPERTENSION; HYPOXIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NATIONAL HEALTH ORGANIZATION; NAUSEA; NEURALGIA; NEUROPATHIC PAIN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN INFECTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CANADA; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PYRAZINES; RECURRENCE; SOCIETIES, MEDICAL;

EID: 79951700533     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.546015     Document Type: Article

References (25)

1. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantiy improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-1992. (Pubitemid 46211378)
2. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-3071. (Pubitemid 39517009)
3. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008.
4. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684. (Pubitemid 40450320)
5. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-639. (Pubitemid 46224241)
6. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-4874. (Pubitemid 46655613)
7. Belch A, Kouroukis CT, Crump M, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18:116-121. (Pubitemid 46152510)
8. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675. [see comment].
9. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520-525.
10. Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001;113:772-778. (Pubitemid 32524402)
11. Savage DG, Rule SA, Tighe M, et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000;11:595-597. (Pubitemid 30431383)
12. Kamat AM, Karashima T, Davis DW, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004;3:279-290. (Pubitemid 39193703)
13. Denlinger CE, Rundall BK, Keller MD, Jones DR. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004;78:1207-1214. (Pubitemid 39303836)
14. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 2004;54:343-353. (Pubitemid 39304429)
15. Ryan DP, Appleman LJ, Lynch T, et al. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 2006;107:2482-2489. (Pubitemid 44748533)
16. Alberts SR, Foster NR, Morton RF, et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 2005;16:1654-1661. (Pubitemid 41510140)
17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253. (Pubitemid 29162950)
18. Thomas DW, Owen RG, Johnson SA, et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma 2005;46:549-552. (Pubitemid 40590032)
19. Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol 2010;151:346-353.
20. Orciuolo E, Buda G, Pelosini M, Petrini M. Fludarabine, bortezomib, myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. Br J Haematol 2010;148:810-812.
21. Weigert O, Weidmann E, Mueck R, et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - longterm results of a multicenter observation study. Leuk Lymphoma 2009;50:716-722.
22. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-565.
23. Barr PM, Fu P, Lazarus HM, et al. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol 2009;147:89-96.
24. Rodriguez J, Gutierrez A, Palacios A, et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 2007;48:2172-2178. (Pubitemid 350107692)
25. Morschhauser F, Depil S, Jourdan E, et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007;18:370-375. (Pubitemid 46331214)